4//SEC Filing
GADICKE ANSBERT 4
Accession 0001231919-25-000507
CIK 0001785530other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 7:20 PM ET
Size
23.1 KB
Accession
0001231919-25-000507
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
MPM BioImpact LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
MPM Oncology Innovations Fund GP LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
UBS Oncology Impact Fund L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes)
GADICKE ANSBERT
10% Owner
Transactions
- Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
MPM ONCOLOGY INNOVATIONS FUND LP
10% Owner
Transactions
- Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
MPM ASSET MANAGEMENT LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-13$0.98/sh−90,951$89,132→ 5,600,240 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-14$0.93/sh−61,640$57,325→ 5,538,600 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-17$0.95/sh−57,061$54,208→ 5,481,539 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology.
- [F2]The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 32,579 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- [F5]The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology.
- [F6]The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology.
- [F9]The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001134655
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 7:20 PM ET
- Size
- 23.1 KB